{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:05:40Z","timestamp":1791335140069,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key-Area Research and Development Program of Shaanxi Province","award":["2023-ZDLSF-41"],"award-info":[{"award-number":["2023-ZDLSF-41"]}]},{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2022YFC2504601"],"award-info":[{"award-number":["2022YFC2504601"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08082-2","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:18:33Z","timestamp":1775639913000},"page":"3121-3130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in na\u00efve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China"],"prefix":"10.1007","volume":"45","author":[{"given":"Jiawei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4884-9065","authenticated-orcid":false,"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"8082_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS (2023) Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med 388:529\u2013542","journal-title":"N Engl J Med"},{"key":"8082_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA et al (2023) Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82:95\u2013106","journal-title":"Ann Rheum Dis"},{"key":"8082_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.509","volume":"5","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang Y, Liu X (2024) Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm 5:e509","journal-title":"MedComm"},{"key":"8082_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe R, Bergstra SA et al (2023) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. ANN RHEUM DIS 82:3\u201318","journal-title":"ANN RHEUM DIS"},{"key":"8082_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102320","volume":"68","author":"CA Fernandez","year":"2023","unstructured":"Fernandez CA (2023) Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients. Curr Opin Pharmacol 68:102320","journal-title":"Curr Opin Pharmacol"},{"key":"8082_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186646","author":"Y Li","year":"2025","unstructured":"Li Y, Gray EH, Ross R et al (2025) Rheumatoid arthritis synovial fluid induces jak-dependent intracellular activation of human sensory neurons. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.186646","journal-title":"JCI Insight"},{"key":"8082_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon LS, Taylor PC, Choy EH et al (2021) The jak\/stat pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51:278\u2013284","journal-title":"Semin Arthritis Rheum"},{"key":"8082_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D et al (2022) Effectiveness of tnf-inhibitors, abatacept, il6-inhibitors and jak-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018jak-pot\u2019 collaboration. ANN RHEUM DIS 81:1358\u20131366","journal-title":"ANN RHEUM DIS"},{"key":"8082_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard-2023-225271","volume":"83","author":"B Hernandez-Cruz","year":"2024","unstructured":"Hernandez-Cruz B, Otero-Varela L, Freire-Gonzalez M et al (2024) Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the biobadaser registry. ANN RHEUM DIS 83:1189\u20131199","journal-title":"ANN RHEUM DIS"},{"key":"8082_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/imj.14028","volume":"48","author":"D Nicholls","year":"2018","unstructured":"Nicholls D, Barrett R, Button P et al (2018) Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: real. Intern Med J 48:1185\u20131192","journal-title":"Intern Med J"},{"key":"8082_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the answer cohort study. Arthritis Res Ther 22:142","journal-title":"Arthritis Res Ther"},{"key":"8082_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00296-016-3649-2","volume":"37","author":"Y Sung","year":"2017","unstructured":"Sung Y, Cho S, Kim D et al (2017) Comparative effectiveness of treatment options after conventional dmards failure in rheumatoid arthritis. Rheumatol Int 37:975\u2013982","journal-title":"Rheumatol Int"},{"key":"8082_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020686","author":"CY Wu","year":"2021","unstructured":"Wu CY, Yang HY, Luo SF, Lai JH (2021) From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22020686","journal-title":"Int J Mol Sci"},{"key":"8082_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2025.100291","volume":"10","author":"C Turesson","year":"2025","unstructured":"Turesson C, Ronnelid J, Kastbom A (2025) Autoantibodies as prognostic markers in rheumatoid arthritis. J Transl Autoimmun 10:100291","journal-title":"J Transl Autoimmun"},{"key":"8082_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"8082_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: american college of rheumatology recommendations for use in clinical practice. Arthritis Care Res 64:640\u20137","journal-title":"Arthritis Care Res"},{"key":"8082_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G et al (2011) American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"8082_CR18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS et al (2015) How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simplified disease activity index? Ann Rheum Dis 74:1132\u20137","journal-title":"Ann Rheum Dis"},{"key":"8082_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244\u2013257","journal-title":"Rheumatology"},{"key":"8082_CR20","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100\u2013S108","journal-title":"Clin Exp Rheumatol"},{"key":"8082_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11739-021-02852-3","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi Y, Xie Y, Zhang G, Feng Y (2022) Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China. Intern Emerg Med 17:703\u2013714","journal-title":"Intern Emerg Med"},{"key":"8082_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 american college of rheumatology guideline for the treatment of rheumatoid arthritis. ARTHRIT CARE RES 73:924\u2013939","journal-title":"ARTHRIT CARE RES"},{"key":"8082_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20959971","volume":"12","author":"J Blaess","year":"2020","unstructured":"Blaess J, Walther J, Petitdemange A et al (2020) Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. Ther Adv Musculoskelet Dis 12:1759720X20959971","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"8082_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02366-x","volume":"22","author":"K Murata","year":"2020","unstructured":"Murata K, Ito H, Hashimoto M et al (2020) Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: kurama cohort. Arthritis Res Ther 22:268","journal-title":"Arthritis Res Ther"},{"key":"8082_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.802934","volume":"8","author":"J Liu","year":"2021","unstructured":"Liu J, Gao J, Wu Z et al (2021) Anti-citrullinated protein antibody generation, pathogenesis, clinical application, and prospects. FRONT MED-LAUSANNE 8:802934","journal-title":"FRONT MED-LAUSANNE"},{"key":"8082_CR26","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA J Am Med Assoc 295:2275\u20132285","journal-title":"JAMA J Am Med Assoc"},{"key":"8082_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70195","volume":"13","author":"S Sasi","year":"2025","unstructured":"Sasi S, Hadi HA, Chaponda M et al (2025) Risk of serious infections in patients treated with biologic or targeted-synthetic disease modifying antirheumatic drugs in Qatar. Immunity Inflamm Dis 13:e70195","journal-title":"Immunity Inflamm Dis"},{"key":"8082_CR28","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H et al (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66:2675\u201384","journal-title":"Arthritis Rheumatol"},{"key":"8082_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70458","volume":"28","author":"OLH Abac","year":"2025","unstructured":"Abac OLH, Olak AF, Yal Nkaya B, Z Akar L (2025) From silicone to synovitis: autoimmune\/inflammatory syndrome induced by adjuvants (asia) in Beh\u00e7et\u2019s disease. Int J Rheum Dis 28:e70458","journal-title":"Int J Rheum Dis"},{"key":"8082_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154273","volume":"241","author":"V Ricci","year":"2023","unstructured":"Ricci V, Ricci C, Tamborrini G et al (2023) From histology to sonography in synovitis: Euro-Musculus\/USPRM approach. Pathol Res Pract 241:154273","journal-title":"Pathol Res Pract"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08082-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:24:54Z","timestamp":1780982694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08082-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8082"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08082-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and approved by the ethics committee of Xijing Hospital (approval number: KY20223526-F-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was duly obtained from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}